NASDAQ:LMDX

LumiraDx (LMDX) Stock Forecast, Price & News

$0.48

-0.02 (-3.25%)

(As of 05/26/2023 08:47 PM ET)

Compare

Today's Range: $0.45
▼
$0.51
50-Day Range: $0.47
▼
$0.86
52-Week Range: $0.45
▼
$4.50

Volume: 150,200 shs
Average Volume: 172,979 shs
Market Capitalization: $152.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.14

LumiraDx MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 346.2% Upside
$2.14 Price Target
Short Interest: Bearish
12.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.51) to ($0.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

746th out of 1,010 stocks

Pharmaceutical Preparations Industry

374th out of 494 stocks

3.3

Analyst's Opinion

Consensus Rating
LumiraDx has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.14, LumiraDx has a forecasted upside of 346.2% from its current price of $0.48.
Amount of Analyst Coverage
LumiraDx has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
12.57% of the float of LumiraDx has been sold short.
Short Interest Ratio / Days to Cover
LumiraDx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in LumiraDx has recently increased by 2.93%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
LumiraDx does not currently pay a dividend.
Dividend Growth
LumiraDx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LMDX.

2.0

News and Social Media Coverage

News Sentiment
LumiraDx has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for LumiraDx this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for LMDX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added LumiraDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, LumiraDx insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.41% of the stock of LumiraDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for LumiraDx are expected to grow in the coming year, from ($0.51) to ($0.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of LumiraDx is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of LumiraDx is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About LumiraDx (NASDAQ:LMDX) Stock

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

LMDX Stock News Headlines

May 21, 2023 | americanbankingnews.com

LumiraDx (NASDAQ:LMDX) Price Target Cut to $1.00

May 20, 2023 | americanbankingnews.com

LumiraDx (NASDAQ:LMDX) Rating Reiterated by 500.com

May 29, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 20, 2023 | americanbankingnews.com

LADENBURG THALM/SH SH Lowers LumiraDx (NASDAQ:LMDX) Price Target to $2.70

May 18, 2023 | msn.com

Ladenburg Thalmann Maintains LumiraDx (LMDX) Buy Recommendation

May 18, 2023 | msn.com

Goldman Sachs Maintains LumiraDx (LMDX) Neutral Recommendation

May 17, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for LumiraDx

May 17, 2023 | msn.com

Raymond James Maintains LumiraDx (LMDX) Outperform Recommendation

May 29, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 17, 2023 | americanbankingnews.com

Short Interest in LumiraDx Limited (NASDAQ:LMDX) Decreases By 6.0%

May 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: LumiraDx (LMDX) and Aerovate Therapeutics (AVTE)

May 16, 2023 | msn.com

LumiraDx: Q1 Earnings Insights

May 16, 2023 | finance.yahoo.com

LumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue Estimates

May 16, 2023 | finanznachrichten.de

LumiraDx Inc: LumiraDx Reports First Quarter 2023 Results

May 16, 2023 | finance.yahoo.com

LumiraDx Reports First Quarter 2023 Results

May 15, 2023 | msn.com

Earnings Preview For LumiraDx

May 9, 2023 | finance.yahoo.com

LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16

May 3, 2023 | finance.yahoo.com

Will LumiraDx Limited (LMDX) Report Negative Q1 Earnings? What You Should Know

May 1, 2023 | americanbankingnews.com

LumiraDx Limited (NASDAQ:LMDX) Short Interest Update

April 24, 2023 | finance.yahoo.com

LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

April 7, 2023 | finance.yahoo.com

Increasing losses over year doesn't faze LumiraDx (NASDAQ:LMDX) investors as stock spikes 30% this past week

April 7, 2023 | americanbankingnews.com

LumiraDx (NASDAQ:LMDX) Given New $1.50 Price Target at Raymond James

April 6, 2023 | finance.yahoo.com

Revamping LumiraDx: New Strategic Focus And Cost-Saving Initiatives Announced

April 6, 2023 | finance.yahoo.com

LumiraDx Announces Strategic Refocus and Cost Restructuring Program

April 2, 2023 | americanbankingnews.com

LumiraDx Limited (NASDAQ:LMDX) Short Interest Up 10.1% in March

March 25, 2023 | americanbankingnews.com

The Goldman Sachs Group Cuts LumiraDx (NASDAQ:LMDX) Price Target to $0.85

March 24, 2023 | finance.yahoo.com

LumiraDx Limited (NASDAQ:LMDX) Q4 2022 Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

LMDX Company Calendar

Last Earnings: 3/21/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/17/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LMDX
CUSIP: N/A
CIK: 1685428
Web: www.lumiradx.com
Phone: 354-640-0540
Fax: N/A
Employees: 1,210
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.14
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $0.85
Forecasted Upside/Downside: +346.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-447,790,000.00
Net Margins: -291.10%
Pretax Margin: -288.53%
Return on Equity: -2,145.42%
Return on Assets: -88.51%

Debt

Debt-to-Equity Ratio: 20.12
Current Ratio: 2.54
Quick Ratio: 1.51

Sales & Book Value

Annual Sales: $254.48 million
Price / Sales: 0.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.48) per share
Price / Book: -1.00

Miscellaneous

Outstanding Shares: 318,550,000
Free Float: 205,749,000
Market Cap: $152.59 million
Optionable: Not Optionable
Beta: 0.96

Key Executives

Mr. Ron Zwanziger (Age 69)
Co-Founder, Chairman & CEO

Dr. David Scott Ph.D. (Age 66)
Co-Founder, CTO & Director

Dr. Jerome F. McAleer Ph.D. (Age 67)
Co-Founder, Chief Scientist & Director

Mr. Dorian LeBlanc CPA (Age 47)
CFO & VP of Global Operations

Ms. Veronique Ameye (Age 46)
Exec. VP & Gen. Counsel

Ms. Colleen McMillen
VP of Communications

Andy Ward
National Sales Director - UK

Mr. Peter Scheu (Age 58)
Pres of North American Commercial Operations

Mr. David Walton DMS (Age 69)
Chief Commercial Officer

Dr. Nigel Lindner (Age 66)
Chief Innovation Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LMDX Stock - Frequently Asked Questions

Should I buy or sell LumiraDx stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LMDX shares.
View LMDX analyst ratings or view top-rated stocks.
What is LumiraDx's stock price forecast for 2023?: 3 analysts have issued 1 year target prices for LumiraDx's shares. Their LMDX share price forecasts range from $0.85 to $4.00. On average, they predict the company's stock price to reach $2.14 in the next twelve months. This suggests a possible upside of 346.2% from the stock's current price.
View analysts price targets for LMDX or view top-rated stocks among Wall Street analysts.
How have LMDX shares performed in 2023?: LumiraDx's stock was trading at $0.90 at the beginning of 2023. Since then, LMDX shares have decreased by 46.8% and is now trading at $0.4790.
View the best growth stocks for 2023 here.
When is LumiraDx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 17th 2023.
View our LMDX earnings forecast.
How were LumiraDx's earnings last quarter?: LumiraDx Limited (NASDAQ:LMDX) announced its quarterly earnings results on Tuesday, March, 21st. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.13. The company earned $41.12 million during the quarter, compared to analyst estimates of $38.41 million. LumiraDx had a negative net margin of 291.10% and a negative trailing twelve-month return on equity of 2,145.42%.
What is LumiraDx's stock symbol?: LumiraDx trades on the NASDAQ under the ticker symbol "LMDX."

Who are LumiraDx's major shareholders?: LumiraDx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Balyasny Asset Management L.P. (0.48%), Beacon Investment Advisory Services Inc. (0.17%) and Sound View Wealth Advisors Group LLC (0.02%).
How do I buy shares of LumiraDx?: Shares of LMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is LumiraDx's stock price today?: One share of LMDX stock can currently be purchased for approximately $0.48.
How much money does LumiraDx make?: LumiraDx (NASDAQ:LMDX) has a market capitalization of $152.59 million and generates $254.48 million in revenue each year. The company earns $-447,790,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.
How many employees does LumiraDx have?: The company employs 1,210 workers across the globe.
How can I contact LumiraDx?: LumiraDx's mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The official website for the company is www.lumiradx.com. The company can be reached via phone at 354-640-0540 or via email at ir@lumiradx.com.

This page (NASDAQ:LMDX) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial